Search peptides, terms, sources/
Metabolic and incretin

Survodutide

Investigational peptide that activates glucagon and GLP-1 receptors. Not authorised in the UK. Studied in phase 3 trials, all sponsor-funded.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Survodutide is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials4 human trials

What is Survodutide?

Survodutide is an investigational synthetic peptide that activates both the glucagon receptor and the GLP-1 receptor, studied in phase 3 trials for weight management, type 2 diabetes with obesity and liver fat. It is not authorised as a medicine in the UK, and the phase 3 trials were all funded by its developer.

Class
Incretin mimetic, Dual glucagon/GLP-1 receptor agonist
Origin
Analogue / modified
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Survodutide work?

Survodutide is described in its phase 3 trial papers as a dual agonist that activates the glucagon receptor and the GLP-1 receptor. GLP-1 receptor activation is the mechanism used by licensed GLP-1 medicines such as semaglutide. The glucagon part is what sets it apart, and how it contributes is a proposed mechanism, not independently confirmed.

The mechanism in more detail

Survodutide is described in its phase 3 trial papers as a dual agonist: it activates the glucagon receptor and the GLP-1 receptor. GLP-1 receptor activation is the same mechanism used by licensed GLP-1 medicines such as semaglutide, which acts on appetite and on glucose-dependent insulin release.

The glucagon receptor part is what sets it apart from single GLP-1 agonists. The trial programme tested liver fat as a main endpoint in people with obesity and liver disease, which fits a proposed role for glucagon receptor activation in the liver. This site cites no dedicated receptor-pharmacology paper for survodutide, so treat the mechanism as proposed rather than independently confirmed.

Classification and structure

Names
Survodutide
Class
Incretin mimetic Dual glucagon/GLP-1 receptor agonist
Origin
Analogue / modified
Structure
A synthetic peptide that acts at the glucagon receptor and the GLP-1 receptor. Exact sequence and modification detail is not given here.
Routes used in the research
Subcutaneous injection in the phase 3 trials where the route is stated. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Survodutide has 4 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

4 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
00220

Phase 3 in obesity without diabetes Strong

In a 76-week, double-blind, placebo-controlled phase 3 trial of 725 adults with obesity and no diabetes (SYNCHRONIZE-1), both survodutide groups lost more weight than placebo: about 12% and 13% of body weight versus about 5% (treatment-regimen estimand). At least 5% weight loss was reached by about 72% of each survodutide group versus 46% on placebo.

Study type
Human trial
Population
725 adults with obesity (BMI 30 or above, or 27 or above with a weight-related complication), without diabetes; phase 3, multicentre, double-blind, placebo-controlled, 76 weeks, with lifestyle counselling in all groups.
Source
1 le Roux et al., 2026

Limitation: Sponsor-funded (Boehringer Ingelheim).

Limitations in full

Sponsor-funded (Boehringer Ingelheim). The abstract reports only the treatment-regimen estimand. Weight loss is an average; individual results varied. Full text not read.

Phase 3 in obesity with type 2 diabetes Strong

In a phase 3 trial of 752 adults with type 2 diabetes and a BMI of 27 or higher (SYNCHRONIZE-2), body weight at week 76 fell by about 8% and 10% in the two survodutide groups versus about 4% on placebo, and HbA1c fell by 0.8 to 0.9 points versus 0.2 on placebo from a baseline of 7.4%.

Study type
Human trial
Population
752 adults with type 2 diabetes and BMI 27 or higher; phase 3, double-blind, randomised 1:1:1 to two survodutide groups or placebo.
Source
2 Wharton et al., 2026

Limitation: Sponsor-funded (Boehringer Ingelheim).

Limitations in full

Sponsor-funded (Boehringer Ingelheim). Abstract read via Europe PMC; full text not read.

Liver fat in obesity with MASLD Moderate

In a 48-week phase 3 trial of 216 adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD), survodutide beat placebo on both co-primary endpoints. A 30% or greater fall in liver fat (MRI) occurred in 84.2% versus 24.3% (efficacy estimand) and 68.5% versus 28.6% (treatment-regimen estimand). Body weight fell 12.2% versus 1.0% and 8.7% versus 1.4% on the same two estimands.

Study type
Human trial
Population
216 adults with obesity and at-risk MASLD, recruited in the United States and Spain; randomised 2:1 to survodutide or placebo.
Source
3 Kaplan et al., 2026

Limitation: Only 48 weeks, two countries, and liver fat measured by imaging, not by clinical liver outcomes.

Limitations in full

Only 48 weeks, two countries, and liver fat measured by imaging, not by clinical liver outcomes. The funding statement is not shown in the record. An author correction exists; its content was not read.

Cardiovascular safety trial Moderate

In a double-blind phase 3 trial of about 5,500 adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT), the main cardiovascular composite occurred in 3.7% of survodutide recipients and 4.1% of placebo recipients (hazard ratio 0.89, 95% CI 0.67 to 1.18), meeting the trial's non-inferiority test. The authors concluded that survodutide was not associated with increased cardiovascular risk.

Study type
Human trial
Population
About 5,500 adults with obesity and established cardiovascular disease, chronic kidney disease or cardiovascular risk factors.
Source
4 Bozkurt et al., 2026

Limitation: Designed to rule out harm, not to show benefit; the confidence interval is wide, spanning a possible 33% fall to an 18% rise.

Limitations in full

Designed to rule out harm, not to show benefit; the confidence interval is wide, spanning a possible 33% fall to an 18% rise. Sponsor-funded. Abstract read via Europe PMC; full text not read.

What safety findings have been reported?

3 safety findings are recorded for Survodutide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Gastrointestinal events, obesity without diabetes

In SYNCHRONIZE-1, gastrointestinal adverse events were the most common and were usually mild to moderate. They occurred in about 81% and 90% of the two survodutide groups versus about 48% of placebo recipients. No deaths were reported in that trial.

Source
1 le Roux et al., 2026

Adverse events, type 2 diabetes

In SYNCHRONIZE-2, adverse events were mostly gastrointestinal, generally mild to moderate and transient. They occurred in about 73% and 78% of the two survodutide groups versus 39% of placebo recipients.

Source
2 Wharton et al., 2026

Cardiovascular safety trial, adverse events

In SYNCHRONIZE-CVOT, nausea and vomiting were much more common with survodutide than with placebo, while serious adverse events were similar across groups.

Source
4 Bozkurt et al., 2026

What is Survodutide's UK regulatory status?

Marketing authorisation
None identified. Survodutide does not appear in the MHRA Products database active-substance index (checked 14 November 2026).
Prescription status
Not applicable; there is no licensed UK product to classify.
Medicine class
Not a licensed medicine in the UK.
MHRA position
No MHRA-authorised product containing survodutide was found in the Products database on 14 November 2026. Absence from the index is a search result on that date, not a regulatory decision.
Authorised use
None in the UK.
Research use
Studied in phase 3 clinical trials (the SYNCHRONIZE programme, run by Boehringer Ingelheim).
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework for unlicensed medicinal products.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Survodutide is recorded as not licensed in the UK (checked 14 November 2026).

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. le Roux CW, Wharton S, Startseva E, et al. (SYNCHRONIZE-1 Investigators) (2026). Survodutide Once Weekly for the Treatment of Adults with Obesity. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2600751 · PMID 42253238 · Original ↗
  2. Wharton S, le Roux CW, Startseva E, et al. (SYNCHRONIZE-2 Investigators) (2026). Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2607219 · PMID 42820639 · Original ↗
  3. Kaplan LM, Startseva E, le Roux CW, et al. (SYNCHRONIZE-MASLD Investigators) (2026). Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature MedicineHuman clinical trial, RCT · DOI 10.1038/s41591-026-04479-3 · PMID 42252333 · Original ↗
  4. Bozkurt B, et al. (SYNCHRONIZE-CVOT Investigators) (2026). Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. The LancetHuman clinical trial, RCT · DOI 10.1016/S0140-6736(26)02140-9 · PMID 43003106 · Original ↗
  5. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Survodutide

What is Survodutide?

Survodutide is an investigational synthetic peptide that activates both the glucagon receptor and the GLP-1 receptor, studied in phase 3 trials for weight management, type 2 diabetes with obesity and liver fat. It is not authorised as a medicine in the UK, and the phase 3 trials were all funded by its developer. Read what it is.

Is Survodutide licensed in the UK?

PeptGuru records Survodutide's UK status as: Not licensed in the UK. None identified. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Survodutide show?

PeptGuru records 4 research findings for Survodutide: 4 from human trials. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Survodutide?

3 safety findings are recorded, including: gastrointestinal events, obesity without diabetes; adverse events, type 2 diabetes; cardiovascular safety trial, adverse events. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Survodutide?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Survodutide added: 4 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Survodutide with Mazdutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.